Current status and future perspectives of drug delivery systems loaded with baicalein and baicalin in cancer therapy

IF 7.5 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Biomedicine & Pharmacotherapy Pub Date : 2025-09-22 DOI:10.1016/j.biopha.2025.118589

Amirreza Nazemiyeh , Samar Mahari , Nima Nazemiyeh , Hossein Abdolmohammadzadeh , Zahra Farshbaf , Athena Rajabzadeh , Somayeh Vandghanooni , Hossein Nazemiyeh , Morteza Eskandani

{"title":"Current status and future perspectives of drug delivery systems loaded with baicalein and baicalin in cancer therapy","authors":"Amirreza Nazemiyeh , Samar Mahari , Nima Nazemiyeh , Hossein Abdolmohammadzadeh , Zahra Farshbaf , Athena Rajabzadeh , Somayeh Vandghanooni , Hossein Nazemiyeh , Morteza Eskandani","doi":"10.1016/j.biopha.2025.118589","DOIUrl":null,"url":null,"abstract":"<div><div>Nano drug delivery systems (NDDSs) have emerged as a transformative approach in cancer therapy, addressing challenges such as drug resistance, poor bioavailability, and off-target toxicity. Baicalein (BA) and baicalin (BI), flavonoids derived from <em>Scutellaria baicalensis</em>, exhibit potent anticancer effects but are limited by low solubility and rapid metabolism. This review classifies BA/BI-loaded NDDS into either organic or inorganic nanoparticles (NPs) and evaluates their current status, focusing on their enhanced pharmacokinetics, targeted delivery, and reduced side effects. We highlight their mechanisms of action, such as induction of apoptosis, inhibition of metastasis, and modulation of signaling pathways (e.g., PI3K/AKT, Wnt/β-catenin), across various cancers, including breast, lung, and colorectal. Preclinical studies demonstrate that BA/BI-loaded NPs significantly improve therapeutic efficacy by leveraging the enhanced permeability and retention (EPR) effect and overcoming multidrug resistance. This review synthesizes these advancements, identifies challenges in clinical translation, such as toxicity and scalability, and proposes future directions for optimizing BA/BI-based NPs for clinical application in oncology.</div></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"192 ","pages":"Article 118589"},"PeriodicalIF":7.5000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedicine & Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0753332225007838","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Nano drug delivery systems (NDDSs) have emerged as a transformative approach in cancer therapy, addressing challenges such as drug resistance, poor bioavailability, and off-target toxicity. Baicalein (BA) and baicalin (BI), flavonoids derived from Scutellaria baicalensis, exhibit potent anticancer effects but are limited by low solubility and rapid metabolism. This review classifies BA/BI-loaded NDDS into either organic or inorganic nanoparticles (NPs) and evaluates their current status, focusing on their enhanced pharmacokinetics, targeted delivery, and reduced side effects. We highlight their mechanisms of action, such as induction of apoptosis, inhibition of metastasis, and modulation of signaling pathways (e.g., PI3K/AKT, Wnt/β-catenin), across various cancers, including breast, lung, and colorectal. Preclinical studies demonstrate that BA/BI-loaded NPs significantly improve therapeutic efficacy by leveraging the enhanced permeability and retention (EPR) effect and overcoming multidrug resistance. This review synthesizes these advancements, identifies challenges in clinical translation, such as toxicity and scalability, and proposes future directions for optimizing BA/BI-based NPs for clinical application in oncology.

查看原文本刊更多论文

黄芩苷和黄芩苷负载给药系统在癌症治疗中的现状和未来展望

纳米给药系统（ndds）已经成为癌症治疗的一种变革性方法，解决了诸如耐药、生物利用度差和脱靶毒性等挑战。黄芩素（Baicalein， BA）和黄芩苷（baicalin， BI）是从黄芩中提取的黄酮类化合物，具有较强的抗癌作用，但由于溶解度低、代谢快而受到限制。本综述将BA/ bi负载的NDDS分为有机或无机纳米颗粒（NPs），并评估了它们的现状，重点关注它们增强的药代动力学、靶向递送和减少的副作用。我们强调了它们的作用机制，如诱导细胞凋亡，抑制转移，调节信号通路（如PI3K/AKT， Wnt/β-catenin），在各种癌症中，包括乳腺癌，肺癌和结直肠癌。临床前研究表明，BA/ bi负载的NPs通过增强渗透性和滞留性（EPR）效应和克服多药耐药，显著提高了治疗效果。这篇综述综合了这些进展，指出了临床转化中的挑战，如毒性和可扩展性，并提出了优化基于BA/ bi的NPs用于肿瘤临床应用的未来方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomedicine & Pharmacotherapy 医学-药学

CiteScore

11.90

自引率

2.70%

发文量

1621

审稿时长

48 days

期刊介绍： Biomedicine & Pharmacotherapy stands as a multidisciplinary journal, presenting a spectrum of original research reports, reviews, and communications in the realms of clinical and basic medicine, as well as pharmacology. The journal spans various fields, including Cancer, Nutriceutics, Neurodegenerative, Cardiac, and Infectious Diseases.